Study eligibility was assessed in 139 patients, with seven patients deemed to be eligible based on the requirement of a HER2− primary tumor and ≥2 CTCs/7.5 mL with ≥50% of CTCs expressing HER2, as assessed using the CellSearch® system. The gene discussed is ERBB2; the disease is neoplasm.